A privately held New York biotech, formerly Kallyope, that rebranded in October 2026 to focus on migraine, raised $94 million ...
Swedish immuno-oncology firm Alligator Bioscience has announced the appointment of Johan Giléus as Alligator’s new chief ...
When a treatment moves from a clinical trial to the real-world post-marketing environment, the increased number of variables can lead to new or rare adverse events. Post-marketing pharmacovigilance ...
Significant research news last week included Mirum Pharmaceuticals releasing positive Phase III data for its hepatitis delta antibody brelovitug and Merck & Co Phase III results for its tulisokibart ...
South Korean biosimilar specialist Samsung Bioepis and Israel’s Teva Pharmaceutical Industries today announced that the ...
Regeneron Pharmaceuticals yesterday announced new results from the Phase II COURAGE trial evaluating trevogrumab ...
Leading Swiss contract development and manufacturing organization (CDMO) Lonza and Asimov, which is building an AI-native ...
The US unit of Teva Pharmaceutical Industries today announced new data for ecopipam, a first-in-class investigational ...
UK pharma major AstraZeneca (LSE: AZN) and Japanese drugmaker Daiichi Sankyo (TSE: 4568) plan to test Datroway (datopotamab ...
US pharma major Johnson & Johnson has made no secret of its ambition to lead the oncology field. The Pharma Letter put that ...
Privately-held Italian drugmaker Italfarmaco and Japan’s JCR Pharmaceuticals have entered an exclusive license agreement to ...
China's Abogen Biosciences, a biotech focused on mRNA therapeutics, has entered a licensing and option agreement with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results